Simpler Grants.gov #FOR-CA-25-089

Forecasted Funding Opportunity for Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations

This forecasted opportunity from the National Cancer Institute (NCI) seeks institutions to serve as Lead Academic Organizations (LAOs) within the Experimental Therapeutics Clinical Trials Network (ETCTN): - The LAOs will: - Design, develop, monitor, conduct, and analyze early phase clinical trials involving investigational agents under NCI's regulatory sponsorship - Oversee scientific, programmatic, financial, and administrative aspects of ETCTN trial sites - Provide mentorship and training for early-career investigators - Ensure all pharmacokinetic studies are conducted through the ETCTN Pharmacokinetic Resource Laboratory - No specific OEMs or commercial vendors are named, as this is a research funding opportunity - Approximately $12 million in total funding is anticipated, with around six awards expected - The funding instrument will be a cooperative agreement (UM1 activity code) - The opportunity is not for procurement of products or equipment, but for research and clinical trial leadership services

Description

The National Cancer Institute (NCI) plans to publish a Notice of Funding Opportunity (NOFO) to solicit applications from institutions to maintain or establish Lead Academic Organizations (LAOs) as part of the ETCTN. These LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials involving agents under regulatory sponsorship for New Investigational Drug applications held by NCI's Division of Cancer Treatment and Diagnosis. The LAOs will oversee scientific, programmatic, financial, and administrative matters related to ETCTN trial sites and provide mentorship for early-stage investigators. The NOFO will use the UM1 activity code and is expected to be published in Summer 2025 with an application due date in Fall 2025.

View original listing